High frequency oscillatory ventilation in newborns with idiopathic persistent pulmonary hypertension

Three consecutive term infants diagnosed as suffering from idiopathic persistent pulmonary hypertension of the newborn (PPHN) were tried on high frequency oscillatory ventilation (HFOV) after failure of conventional mechanical ventilation (CMV). All experienced a significant improvement in oxygenation. All three infants survived. HFOV was utilised in a fourth term infant initially diagnosed as having idiopathic PPHN with an immediate benefit. This infant subsequently died and was found at autopsy to have a lethal congenital maldevelopment of pulmonary microcirculation. No serious adverse effects were encountered with HFOV in contrast to the use of pharmacologic agents where hypotension was a serious problem. A therapeutic trial of HFOV is simple and efficient, and would not cause undue delay in the commencement of other rescue therapy should it prove unsuccessful. We predict HFOV will replace non-specific vasoactive agents as the standard first line alternative to CMV for the treatment of idiopathic PPHN.